Key result
Severe multimorbidity post-MI is linked to a ~5 point lower EQ-VAS score versus mild multimorbidity.
Why the study?
Multimorbidity is common in myocardial infarction, but previous studies had examined single health conditions in isolation.
Cohort (n=9,566)
Yes
Effect estimate: Adjusted coefficient -5.12 (95% CI -7.04 to -3.19)
p-value: p=<0.001
Among MI survivors, severe multimorbidity is significantly associated with persistently lower health-related quality of life across multiple domains up to 12 months post-MI.
Severe multimorbidity may identify MI survivors needing HRQoL support; hypothesis-generating for targeted interventions, requiring prospective trials.
BACKGROUND: Multimorbidity is prevalent for people with myocardial infarction (MI), yet previous studies investigated single-health conditions in isolation. We identified patterns of multimorbidity in MI survivors and their associations with changes in HRQoL. METHODS: In this national longitudinal cohort study, we analysed data from 9566 admissions with MI from 77 National Health Service hospitals in England between 2011 and 2015. HRQoL was measured using EuroQol 5 dimension (EQ5D) instrument and visual analogue scale (EQVAS) at hospitalisation, 6, and 12 months following MI. Latent class analysis (LCA) of pre-existing long-term health conditions at baseline was used to identify clusters of multimorbidity and associations with changes in HRQoL quantified using mixed effects regression analysis. RESULTS: Of 9566 admissions with MI (mean age of 64.1 years [SD 11.9], 7154 [75%] men), over half (5119 [53.5%] had multimorbidities. LCA identified 3 multimorbidity clusters which were severe multimorbidity (591; 6.5%) with low HRQoL at baseline (EQVAS 59.39 and EQ5D 0.62) which did not improve significantly at 6 months (EQVAS 59.92, EQ5D 0.60); moderate multimorbidity (4301; 47.6%) with medium HRQoL at baseline (EQVAS 63.08, EQ5D 0.71) and who improved at 6 months (EQVAS 71.38, EQ5D 0.76); and mild multimorbidity (4147, 45.9%) at baseline (EQVAS 64.57, EQ5D 0.75) and improved at 6 months (EQVAS 76.39, EQ5D 0.82). Patients in the severe and moderate groups were more likely to be older, women, and presented with NSTEMI. Compared with the mild group, increased multimorbidity was associated with lower EQ-VAS scores (adjusted coefficient: -5.12 [95% CI -7.04 to -3.19] and -0.98 [-1.93 to -0.04] for severe and moderate multimorbidity, respectively. The severe class was more likely than the mild class to report problems in mobility, OR 9.62 (95% confidence interval: 6.44 to 14.36), self-care 7.87 (4.78 to 12.97), activities 2.41 (1.79 to 3.26), pain 2.04 (1.50 to 2.77), and anxiety/depression 1.97 (1.42 to 2.74). CONCLUSIONS: Among MI survivors, multimorbidity clustered into three distinct patterns and was inversely associated with HRQoL. The identified multimorbidity patterns and HRQoL domains that are mostly affected may help to identify patients at risk of poor HRQoL for which clinical interventions could be beneficial to improve the HRQoL of MI survivors. TRIAL REGISTRATION: ClinicalTrials.gov NCT01808027 and NCT01819103.
No takes yet. Share an insight, caveat, or question.
Munyombwe et al. (2021) conducted a cohort in Myocardial infarction (n=9,566). Severe multimorbidity vs. Mild multimorbidity was evaluated on EQ-VAS score (Adjusted coefficient -5.12, 95% CI -7.04 to -3.19, p=<0.001). Severe multimorbidity in myocardial infarction survivors was associated with significantly lower health-related quality of life EQ-VAS scores compared to mild multimorbidity (adjusted coefficient -5.12).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: